RSS

pulmonary arterial hypertension (PAH)

New research from scientists at the Université Paris-Saclay has revealed a novel approach to the cessation of arterial deterioration in pulmonary arterial hypertension (PAH) patients. more

News

New research from Imperial College London, that has recently been published online, examined a novel type of nanoparticle called metal organic frameworks (MOF) as drug carriers for the treatment of pulmonary arterial hypertension (PAH). more

News

The European Medicines Agency (EMA) has concluded its review of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH), confirming it can be continued to be used, according to the prescribing information. more

News